Presidential Advisory Council on HIV/AIDS, International Issues Subcommittee [Transcript]

16
1 capacity. It has nothing to do with intelligence. I'm
2 talking here about experience. David Baltimore should be
3 on the committee, but perhaps he shouldn't be the chair.
4 RABBI EDELHEIT: So I just want to make sure I
5 heard you correctly. Given the overall paralysis, you are
6 now no longer as concerned about --
7 DR. MANN: It's a non-starter. It's not a lack
8 of concern, Rabbi. It's not a lack of concern, but you
9 can't get people to focus on the question of how to make a
10 vaccine universally available when the prevailing climate,
11 the prevailing word out there, generated by just a few --
12 RABBI EDELHEIT: Okay.
13 DR. WENIGER: I sort of asked that question
14 about vaccine development experience in the last couple of
15 years of looking at this issue. When the Levine committee
16 was reviewing NIH, they had an AIDS vaccine panel, and
17 there were 16 people on that panel, and I did Medline
18 literature searches back to the beginning of the
19 computerized Medline in 1965, and only about three or four
20 out of those 16 could I find any published scientific
21 article about any vaccine for human or veterinary use.
22 The majority of the people on that panel, as
23 well as the vaccine working group in 1994, as well as the
24 AIDS Research Advisory Committee in 1994 that voted against
25 conducting these field trials that you're talking about,
26 those people with experience in developing vaccines are in

FREILICHER & ASSOCIATES, COURT REPORTERS
[phone]